← All MEPs

Mathilde Androuët

European Parliament · PfE · 🇫🇷 France

Term: since 18 July 2019

Participation in roll-call votes

93 % of the 2,540 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % July 2019 : participation 100 % (1 / 1), presence 100 % (1 / 1) 2019 September 2019 : participation 100 % (5 / 5), presence 100 % (5 / 5) October 2019 : participation 100 % (19 / 19), presence 100 % (19 / 19) November 2019 : participation 100 % (18 / 18), presence 100 % (18 / 18) December 2019 : participation 100 % (6 / 6), presence 100 % (6 / 6) January 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) 2020 February 2020 : participation 100 % (8 / 8), presence 100 % (8 / 8) May 2020 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 100 % (19 / 19), presence 100 % (19 / 19) September 2020 : participation 100 % (24 / 24), presence 100 % (24 / 24) October 2020 : participation 100 % (37 / 37), presence 100 % (37 / 37) November 2020 : participation 100 % (32 / 32), presence 100 % (32 / 32) December 2020 : participation 100 % (30 / 30), presence 100 % (30 / 30) January 2021 : participation 100 % (23 / 23), presence 100 % (23 / 23) 2021 February 2021 : participation 100 % (21 / 21), presence 100 % (21 / 21) March 2021 : participation 100 % (31 / 31), presence 100 % (31 / 31) April 2021 : participation 100 % (81 / 81), presence 100 % (81 / 81) May 2021 : participation 100 % (26 / 26), presence 100 % (26 / 26) June 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) July 2021 : participation 100 % (27 / 27), presence 100 % (27 / 27) September 2021 : participation 100 % (19 / 19), presence 100 % (19 / 19) October 2021 : participation 100 % (42 / 42), presence 100 % (42 / 42) November 2021 : participation 96 % (26 / 27), presence 96 % (26 / 27) December 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2022 : participation 70 % (26 / 37), presence 70 % (26 / 37) April 2022 : participation 0 % (0 / 22), presence 0 % (0 / 22) May 2022 : participation 84 % (74 / 88), presence 84 % (74 / 88) June 2022 : participation 48 % (22 / 46), presence 48 % (22 / 46) July 2022 : participation 97 % (30 / 31), presence 97 % (30 / 31) September 2022 : participation 64 % (16 / 25), presence 64 % (16 / 25) October 2022 : participation 97 % (31 / 32), presence 97 % (31 / 32) November 2022 : participation 97 % (37 / 38), presence 97 % (37 / 38) December 2022 : participation 89 % (16 / 18), presence 89 % (16 / 18) January 2023 : participation 63 % (10 / 16), presence 63 % (10 / 16) 2023 February 2023 : participation 21 % (6 / 29), presence 21 % (6 / 29) March 2023 : participation 100 % (29 / 29), presence 100 % (29 / 29) April 2023 : participation 92 % (22 / 24), presence 92 % (22 / 24) May 2023 : participation 100 % (93 / 93), presence 100 % (93 / 93) June 2023 : participation 90 % (36 / 40), presence 90 % (36 / 40) July 2023 : participation 98 % (39 / 40), presence 98 % (39 / 40) September 2023 : participation 59 % (16 / 27), presence 59 % (16 / 27) October 2023 : participation 65 % (26 / 40), presence 65 % (26 / 40) November 2023 : participation 96 % (51 / 53), presence 96 % (51 / 53) December 2023 : participation 95 % (38 / 40), presence 95 % (38 / 40) January 2024 : participation 100 % (49 / 49), presence 100 % (49 / 49) 2024 February 2024 : participation 100 % (63 / 63), presence 100 % (63 / 63) March 2024 : participation 100 % (50 / 50), presence 100 % (50 / 50) April 2024 : participation 100 % (212 / 213), presence 100 % (212 / 213) July 2024 : participation 100 % (1 / 1), presence 100 % (1 / 1) September 2024 : participation 100 % (8 / 8), presence 100 % (8 / 8) October 2024 : participation 85 % (11 / 13), presence 85 % (11 / 13) November 2024 : participation 100 % (27 / 27), presence 100 % (27 / 27) December 2024 : participation 100 % (18 / 18), presence 100 % (18 / 18) January 2025 : participation 100 % (6 / 6), presence 100 % (6 / 6) 2025 February 2025 : participation 80 % (8 / 10), presence 80 % (8 / 10) March 2025 : participation 100 % (14 / 14), presence 100 % (14 / 14) April 2025 : participation 27 % (6 / 22), presence 27 % (6 / 22) May 2025 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2025 : participation 95 % (21 / 22), presence 95 % (21 / 22) July 2025 : participation 94 % (30 / 32), presence 94 % (30 / 32) September 2025 : participation 97 % (28 / 29), presence 97 % (28 / 29) October 2025 : participation 98 % (44 / 45), presence 98 % (44 / 45) November 2025 : participation 98 % (50 / 51), presence 98 % (50 / 51) December 2025 : participation 97 % (30 / 31), presence 97 % (30 / 31) January 2026 : participation 95 % (21 / 22), presence 95 % (21 / 22) 2026 February 2026 : participation 96 % (27 / 28), presence 96 % (27 / 28) March 2026 : participation 100 % (44 / 44), presence 100 % (44 / 44) April 2026 : participation 100 % (51 / 51), presence 100 % (51 / 51) May 2026 : participation 100 % (25 / 25), presence 100 % (25 / 25) June 2026 : participation 97 % (34 / 35), presence 97 % (34 / 35) July 2026 : participation 100 % (35 / 35), presence 100 % (35 / 35) September 2026 : participation 98 % (39 / 40), presence 98 % (39 / 40) October 2026 : participation 94 % (50 / 53), presence 94 % (50 / 53) November 2026 : participation 100 % (13 / 13), presence 100 % (13 / 13)

Their votes

2,540 votes

DateTextResultTheir vote
Implementation of the common commercial policy – annual report 2018 Against
The Establishment of an EU Mechanism on Democracy, the Rule of Law and Fundamental Rights Against
The European Year of Greener Cities 2022 Against
COVID-19: EU coordination of health assessments and risk classification, and the consequences for Schengen and the single market Against
The cultural recovery of Europe For
The draft Commission regulation amending Annexes II, III and IV to Regulation (EC) No 396/2005 as regards maximum residue levels for cycloxydim, flonicamid, haloxyfop, mandestrobin, mepiquat, Metschnikowia fructicola strain NRRL Y-27328 and prohexadione in or on certain products For
Measures for a sustainable rail market in view of the COVID-19 pandemic For
The humanitarian situation in Mozambique For
The case of Dr. Denis Mukwege in the Democratic Republic of the Congo (DRC) For
The situation in the Philippines, including the case of Maria Ressa Abstention
Resolution on the situation in Russia: the poisoning of Alexei Navalny Against
The situation in Belarus Against
The preparation of the special European Council summit focusing on the dangerous escalation and the role of Turkey in the Eastern Mediterranean Against
Report on the implementation of National Roma Integration Strategies: Combating negative attitudes towards people with Romani background in Europe Against
Shortage of medicines - how to address an emerging problem For
Maximising the energy efficiency potential of the EU building stock Abstention
A strategic approach to pharmaceuticals in the environment For
Determination of a clear risk of a serious breach by Poland of the rule of law Against
Annual report on arms export Against
Just Transition Fund Abstention
Real Driving Emissions  (RDE) Against
Annual implementing report on the EU association agreement with Georgia Against
Carbon dioxide emissions from maritime transport: global data collection system for ship fuel oil consumption data Against
Union Civil Protection Mechanism Against
EU-African security cooperation in the Sahel region, West Africa and the Horn of Africa Abstention
The EU’s role in protecting and restoring the world’s forests For
The conclusions of the extraordinary European Council meeting of 17-21 July 2020 Against
Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or pent coronavirus disease Against
Emission limits and type-approval for internal combustion engines for non-road mobile machinery: transitional provisions in order to address the impact of COVID-19 crisis For
The revision of the guidelines for trans-European energy infrastructure Abstention
The EU’s public health strategy post-COVID-19 Against
A comprehensive Union policy on preventing money laundering and terrorist financing – the Commission’s Action Plan and other recent developments Abstention
The Chemicals Strategy for Sustainability For
European Parliament recommendation to the Council and the Commission concerning the conclusion of an agreement, under negotiation, between the European Union and New Zealand on the exchange of personal data between the European Union Agency for Law Enforcement Cooperation (Europol) and the New Zealand authorities competent for fighting serious crime and terrorism For
A comprehensive European approach to energy storage Abstention
The draft Commission implementing regulation amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, dimethomorph, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, formetanate, metribuzin, milbemectin… For
Objection pursuant to Rule 112(2) and (3): Certain uses of chromium trioxide Against
Mobilisation of the Contingency Margin in 2020: continuation of humanitarian support to refugees in Turkey Against
Amending budget 5/2020: continuation of the support to refugees and host communities in response to the Syria crisis in Jordan, Lebanon and Turkey Against
Guidelines for the employment policies of the Member States Against

Rows per page: 20 40 100 200 All